Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Retained Earnings (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Retained Earnings for 7 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.07% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 100.07% year-over-year, with the annual reading at $1.1 million for FY2025, 100.07% up from the prior year.
  • Retained Earnings for Q4 2025 was $1.1 million at Beam Therapeutics, up from -$1.9 billion in the prior quarter.
  • The five-year high for Retained Earnings was $1.8 million in Q3 2024, with the low at -$1.9 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$494.8 million, with a median of -$3.6 million recorded in 2022.
  • The sharpest move saw Retained Earnings plummeted 8536277.78% in 2021, then surged 124.86% in 2023.
  • Over 5 years, Retained Earnings stood at -$768.3 million in 2021, then skyrocketed by 99.68% to -$2.4 million in 2022, then soared by 124.86% to $604000.0 in 2023, then plummeted by 259475.99% to -$1.6 billion in 2024, then surged by 100.07% to $1.1 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $1.1 million, -$1.9 billion, and $10000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.